42 results about "Luteal phase" patented technology

The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulator include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms.

The present invention concerns the use of an agonist of an hypothalamic hormone for the preparation of a pharmaceutical agent to support the luteal phase during infertility treatment of female mammals and more specifically of woman. According to this invention, the pharmaceutical agent is suitable to be used for supporting the luteal phase after a spontaneous ovulation or after stimulation of follicular growth, trigger of final follicular maturation and ovulation with one or several additional agents.

A method for preventing or treating a catamenial migrainous disorder in a female subject comprises administering to a vulvovaginal surface of the subject a pharmaceutical composition that is bioadhesive thereto and comprises at least one estrogenic compound in an amount of about 50 μg to about 1000 μg estradiol equivalent per unit dose of the composition. A related method comprises administering to a vulvovaginal surface of the subject a pharmaceutical composition comprising at least one estrogenic compound, wherein upon administration of the composition to the vulvovaginal surface, a decline in serum estradiol concentration during a luteal phase of a menstrual cycle is moderated.

The present invention relates to a method of treating disorders including cognition impairment, generalized anxiety disorder, acute stress disorder, social phobia, simple phobias, pre-menstrual dysphoric disorder, social anxiety disorder, major depressive disorder, eating disorders, obesity, anorexia nervosa, bulimia nervosa, binge eating disorder, substance abuse disorders, chemical dependencies, nicotine addiction, cocaine addiction, alcohol addiction, amphetamine addiction, Lesch-Nyhan syndrome, neurodegenerative diseases, late luteal phase syndrome, narcolepsy, psychiatric symptoms anger, rejection sensitivity, movement disorders, extrapyramidal syndrome, Tic disorder, restless leg syndrome, tardive dyskinesia, sleep related eating disorder, night eating syndrome, stress urinary incontinence, migraine, neuropathic pain, diabetic neuropathy, fibromyalgia syndrome, chronic fatigue syndrome, sexual dysfunction, premature ejaculation, and male impotence. This method involves administering to a patient in need of such treatment a therapeutically effective amount of a disclosed compound. Such compounds are 4-phenyl substituted tetrahydroisoquinolines having the Formula IA, IB, IIA, IIB, IIIA or IIIC as set forth herein.

The present invention relates to a method of treating disorders including cognition impairment, generalized anxiety disorder, acute stress disorder, social phobia, simple phobias, pre-menstrual dysphoric disorder, social anxiety disorder, major depressive disorder, eating disorders, obesity, anorexia nervosa, bulimia nervosa, binge eating disorder, substance abuse disorders, chemical dependencies, nicotine addiction, cocaine addiction, alcohol addiction, amphetamine addiction, Lesch-Nyhan syndrome, neurodegenerative diseases, late luteal phase syndrome, narcolepsy, psychiatric symptoms anger, rejection sensitivity, movement disorders, extrapyramidal syndrome, Tic disorder, restless leg syndrome, tardive dyskinesia, sleep related eating disorder, night eating syndrome, stress urinary incontinence, migraine, neuropathic pain, diabetic neuropathy, fibromyalgia syndrome, chronic fatigue syndrome, sexual dysfunction, premature ejaculation, and male impotence. This method involves administering to a patient in need of such treatment a therapeutically effective amount of a disclosed compound. Such compounds are 4-phenyl substituted tetrahydroisoquinolines having the Formula IA, IB, IIA, IIB, IIIA or IIIC as set forth herein.

The present invention relates to the use of an oxytocin receptor antagonist in females undergoing embryo transfer as part of an assisted reproductive technology. In particular, methods are provided for increasing ongoing implantation rate, increasing ongoing pregnancy rate, increasing clinical pregnancy rate, and / or increasing live birth rate in a female subject undergoing embryo transfer. Specifically, the antagonists are released in the luteal phase when the endometrium is receptive for embryo implantation and / or when the embryo has reached the blastocyst-stage.

One aspect of the present invention relates to heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. A second aspect of the invention relates to the use of a compound of the invention for modulation of a mammalian nicotinic acetylcholine receptor. The present invention also relates to the use of a compound of the invention for treating a mammal suffering from Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism or trichtillomania.

The present invention relates to the use of an oxytocin receptor antagonist in females undergoing embryo transfer as part of an assisted reproductive technology. In particular, methods are provided for increasing ongoing implantation rate, increasing ongoing pregnancy rate, increasing clinical pregnancy rate, and / or increasing live birth rate in a female subject undergoing embryo transfer. Specifically, the antagonists are released in the luteal phase when the endometrium is receptive for embryo implantation and / or when the embryo has reached the blastocyst-stage.

The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulator include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase type 4.

One aspect of the present invention relates to heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. A second aspect of the invention relates to the use of a compound of the invention for modulation of a mammalian nicotinic acetylcholine receptor. The present invention also relates to the use of a compound of the invention for treating a mammal suffering from Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism or trichtillomania.

The invention discloses a traditional Chinese medicine composition for treating luteal phase defect type infertility and menstrual disorder. The traditional Chinese medicine composition disclosed by the invention is prepared from the following components in parts by weight: 1-6 parts of fried radix paeoniae alba, 1-9 parts of common yam rhizome, 1-6 parts of dogwood, 0.5-3 parts of vinegar baked bupleurum root, 1-9 parts of the seed of Chinese dodder, 1.5-9 parts of sliced cornu cervi, 1.5-9 parts of amethyst and 1-6 parts of radix salviae miltiorrhizae. According to the compound composition provided by the invention, by means of syndrome differentiation and treatment, the formula is obtained through a lot of experimental screening under the guidance of theories of traditional Chinese medicines; experimental results show that the traditional Chinese medicine composition is capable of improving the structure and form of ovary mitochondria endoplasmic reticulum, improving structures of endometrial glands and mesenchyme, adjusting ovary secreted active substances E2 and P, reducing endometrium estrogen receptors and progestrone receptors and increasing expression of integrins alpha v and beta 3; therefore, the endometrium receptivity can be increased; the embryo implantation action is promoted; the traditional Chinese medicine composition has the good effect for treating infertility; and furthermore, the traditional Chinese medicine composition is free from toxic and side effect, and safe and reliable to use.

The invention discloses a Chinese medicinal preparation for treating luteal phase defect type infertility. The luteal phase defect type infertility belongs to the domain of medical 'infertility' and 'preceded menorrhea'. The luteal phase defect type infertility seldom has specific symptoms except infertility, preceded menorrhea or dripping wet ungodliness and abortion in clinic. Japanese angelica tree root bark, orchis, hypoxis, Chinese holly bark, cynanchum mooreanum, combretum, flatstem milkvetch seeds, phoenix hawksbeard root, rhizoma cibotii, vetch, oroxylum indicum vent and eclipta are decocted with water. Through clinical trials, the total effective rate reaches 96% and is obviously superior to that of the contrast group, so the Chinese medicinal preparation is worthy of clinical popularization and application.

A traditional Chinese medicinal pill for treating gynopathy is prepared through the following steps: mixing raw medicines, grinding the obtained mixture to form powder, and adding 200-300 parts by weight of yellow rice wine, wherein the raw medicines comprise, by weight, 20-60 parts of Rhizoma Cyperi processed with wine, vinegar, ginger and salt, 10-50 parts of Chinese angelica root, 5-30 parts of Ligusticum wallichii, 10-50 parts of white peony root, 10-50 parts of unprocessed rehmannia root, 10-50 parts of Poria cocos, 10-50 parts of Fructus Aurantii, 5-30 parts of Magnolia officinalia Rehd et wils, 5-25 parts of Areca catechu, 10-50 parts of Radix Astragali preparata, 15-25 parts of corydalis tuber, 5-20 parts of pinellia tuber, 10-50 parts of dried orange peel, 10-55 parts of prepared rehmannia root, 10-50 parts of safflower, 10-50 parts of Rhizoma Atractylodis Macrocephalae and 10-35 parts of honey-fried licorice root. The traditional Chinese medicinal pill has the advantages of reasonable compatibility, simple preparation method and no toxic or side effects, can activating blood circulation to dissipate blood stasis, rectify qi, relieve pains, soften hardness, dissipate binds, regulate menstruation, relieve leucorrhea, remove inflammation and kill bacteria, and especially has very substantial curative effects on mastopathy, fibroid, ovarian cyst, abnormal menstruation, dysmenorrhoea, pelvic inflammation, cervical erosion, colpitis, pruritus vulvue, luteal phase defect, infertility and other gynaecologic diseases.

A method of treating infertility disorders by 1) administering an LH-RH antagonist, preferably Cetrorelix, in amounts to selectively suppress endogenous LH but not FSH secretion and 2) inducing follicle growth by administration of exogenous gonadotropin. The selective suppression OF LH allows FSH secretion to be at natural levelS thereby not affecting individual estrogen development. The LH-RH antagonist can be given as a single or dual subcutaneous dose in the range of 1 mg to 10 mg, preferably 2 mg-6 mg. In multiple dosing-posology, LH-RH antagonist can be administered subcutaneously in an amount in the range of 0.1 to 0.5 mg of LH-RH antagonist / day. LH-RH antagonist is applied starting cycle day 1 to 10, preferably on day 4 to 8, and ovulation can be induced between day 9 and 20 of the menstruation cycle by administering rec. LH, native LH-RH, LH-RH agonist or by HCG. In addition rec. LH, native LH-RH or LH-RH agonist can be given to avoid hyperstimulation syndrome and native LH-RH or a LH-RH agonist can be administered to avoid luteal phase stimulation by neutralizing the negative effects of HCG.

Premenstrual syndrome (PMS) refers to a group of symptom complex repeatedly occurring 7-14 days before menstruation (namely in a luteal phase of a menstrual cycle), affecting women daily life and work and relating to bodies, spirit and behavior, the symptom disappears naturally after menses, and about 90% of women of child-bearing age are estimated to have at least one PMS. The invention aims to provide a pharmaceutical composition for treating premenstrual tension syndrome and a preparation method thereof. The pharmaceutical composition is composed of radix bupleuri, cape jasmine, malt, radix rhapontied and siphonostegia chinensis. The pharmaceutical composition has the functions of soothing liver and relieving depression, regulating qi to alleviate pain, and promoting blood circulation to regulate menstruation, and is used for liver qi unfavorable prognosis syndrome of the premenstrual tension syndrome. The preparation method of the pharmaceutical composition comprises the steps: extracting and concentrating the pharmaceutical composition with water or an appropriate concentration of ethanol or concentrating after recovery of the ethanol, removing impurities, drying, mixing with suitable auxiliary materials, and preparing a pharmaceutically acceptable preparation.

The invention relates to the technical field of water buffalo breeding, and particularly relates to a method for improving the hybridization efficiency of water buffaloes. According to the invention,an artificial luteal phase is made by injecting a gonadotropin releasing hormone analogue into muscle, so that follicle maturation is inhibited; then chloroprostolis injected for dissolving functionalcorpus luteum, and the gonadotropin releasing hormone analogue is repeatedly injected into the muscle, so that female water buffaloes are oestrous after the injection; timely semen delivery and hybridization are carried out; an early-stage pregnancy test is carried out on the female water buffaloes in the 28th day after the hybridization, so that pregnant female water buffaloes and nonpregnant water buffaloes can be rapidly distinguished; and grouping management is carried out on the female water buffaloes. According to the method, two-time synchronization treatment and two-time hybridizationare continuously carried out on the same group of female water buffaloes, so that the conception rate of the group can be improved; and the early-stage pregnancy detection technology in the 28th dayis used for replacing a B-type ultrasonic pregnancy diagnosis technology in the 35th day, so that the hybridization waiting time of the female water buffaloes can be shortened, and the feeding cost ofthe female water buffaloes is reduced.

The invention relates to a medicine for treating anovulatory dysfunctional uterine bleeding. Common symptom of anovulatory dysfunctional uterine bleeding is irregular metrorrhagia and is represented by irregular menstrual periods, unequal menstrual periods, indefinite or increased menstrual blood volume, and even excessive bleeding. No stomachache or other discomforts are available in the full bleeding period, secondary anemia always occurs when the amount of bleeding is great or the time is long, and excessive bleeding leads to shock. No abnormalities are found in general check-up and gynecologic examination, so that organic lesions of reproductive organ and general lesions are excluded. Ovulation is stopped through endometrium sample pathological examination, progesterone test in luteal phase and examination of basal body temperature. Through long-term research and clinical verification, the inventor finally finds a traditional Chinese medicine oral preparation for treating anovulatory dysfunctional uterine bleeding with better curative effect. The use level of medical components are found by the inventer, and the medicine comprises the components in parts by weight as follows: 10 parts of angelica sinensis, 10 parts of ligusticum wallichii, 10 parts of myrrh, 10 parts of trogopterus dung, 3 parts of pseudo-ginseng, 12 parts of the root bark of the peony tree, 10 parts of the root of red-rooted salvia, 6 parts of donkey-hide gelatin, 15 parts of fried folium artemisiae argyi, 20 parts of cuttle bone, 20 parts of keel and 15 parts of oyster. The medicines are combined, so that the medicines have the synergistic effect, and have the functions of promoting blood circulation to remove blood stasis, nourishing the blood and hemoslasis and regulating menstruation and relieving pain, so that the medicine can effectively treat anovulatory dysfunctional uterine bleeding.

The invention provides a traditional Chinese medicine composition for shortening mare luteal phase, and the traditional Chinese medicine composition comprises the following raw materials: toosendan fruit, bupleurum, semen litchi, fennel, frankincense, notopterygium and radix angelicae pubescentis. The traditional Chinese medicine composition uses the therapeutic principle of warming spleen and stomach for dispelling cold and benefiting qi for lifting yang, and is reasonable in prescription, simple in preparation process and wide in scope of application. The traditional Chinese medicine composition is prepared from pure Chinese herbal medicines, and is wide in source, low in cost, high in cure rate, free of medicine residue, and free of toxic and side effects. In particularly, after super fine crushing, maximum destruction of plant cell walls can be realized by the traditional Chinese medicine composition, and the traditional Chinese medicine composition solves the deficiency that traditional medicine powder is high in crude fiber content, and effective components are not easy to dissolving out, and is easy for absorption of horses. The traditional Chinese medicine composition has the effects of relieving, easing pains, and regulating body functions, effectively shortens the mare luteal phase, can shorten the recovery period, compared with western medicine treatment, and is free of recurrence.

The invention discloses activating molecule essential oil for the female luteal phase and a making method thereof. The activating molecule essential oil is prepared from, by weight, 8-20 parts of grape seed oil, 6-15 parts of rose oil, 3-8 parts of sweet orange peel oil, 4-10 parts of bergamot fruit oil, 7-12 parts of tea oil, 8-16 parts of eucalyptus globulus leaf oil, 3-7 parts of mint oil, 2-8parts of lavender oil, 5-14 parts of tocopherol, 20-30 parts of octyldodecanol oleate, 20-30 parts of argania spinosa kernel oil, 5-10 parts of egg yolk oil, 5-10 parts of squalane and 25-40 parts ofdicaprylyl carbonate. The making method for the activating molecule essential oil for the female luteal phase includes the multiple technology steps of preparing base oil, preparing essential oil, mixing and the like; after using, it is avoided that as follicles perish, and endometrium is about to fall off, the face gets pimples, and is exuberant in grease secretion and coarse in pore, all kinds of physiological pain discomfort such as blocking, pains, sensitivity, breast distending pains, abdominal distention and constipation of the body occur, and phenomena that the spirit is tense, fractious, somber, agitated and the like occur; after the liver and the gall are dredged, an effect of soothing the liver and regulating qi can be achieved.

A healthcare product for women in the menstrual period is prepared from raw material in parts by weight as follows: 10-20 parts of edible mushrooms, 15-20 parts of nuts, 2-8 parts of soybeans, 5-15 parts of quinoa, 8-12 parts of prebiotics and 1-5 parts of an antioxidant. When taken by the women in the first week of a luteal phase, the healthcare product has the advantages that follicular development can be promoted, estrogen can be supplemented, ovulation can be promoted, the kidney can be strengthened and tonified, the liver can be soothed, vital energy can be regulated, gastrointestinal functions can be coordinated, and bowel movement of the intestinal tract can be promoted.

The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulator include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms.

The present invention discloses a method for increasing the timed insemination efficiency of gilts. The method includes: selecting healthy gilts with suitable ages, intramuscularly injecting 1000 IU of PMSG per gilt, and starting to execute a timed insemination program after 15-20 d. PMSG pretreatment on the silts is preformed at the early stage of a conventional timed insemination program to provide a follicular development process for the gilts, so that the gilts are in an artificial known estrus before the conventional timed insemination program, that is, a follicular luteal phase begins from the 15th d, a follicular development period begins from the 20th d, and the initial follicular development states of the overall population are consistent and controllable. Shown by a result, the consistency of the initial follicular states may increase the pregnancy rate, the total number of births and the number of live births after timed insemination program processing, so that the overall efficiency of timed insemination of the gilts is increased, defects of an existing program are effectively overcome, an existing timed insemination program is optimized, the reproduction performance ofthe gilts is increased, and thus, the economic benefit of a pig farm is increased.

1. Name of the product in this design: Graphical User Interface for Marking Female Menstrual Cycle Information in Electronic Devices. 2. Intended use of this design: for use in an electronic device. 3. The key design features of this product are the graphical user interface displayed on the screen panel. 4. The picture or photo that best illustrates the key design points: Design 1 front view. 5. Design 1 is designated as the basic design. 6. Description of the changing states of the graphical user interface: This graphical user interface is used for women's menstrual cycle. Design 1's main view is the homepage interface for a woman's menstrual cycle. When the APP enables intelligent prediction, and the menstrual cycle is in the luteal phase, the main view of Design 1 will automatically jump to the interface change state diagram 1 of Design 1. When the menstrual period begins during the luteal phase, clicking "Mark Start" in the Design 1 interface change state diagram 1 will redirect the Design 1 interface change state diagram 2, indicating the start of the menstrual period and the beginning of menstrual period recording. Design 1: Interface Changes (Figure 2) will change accordingly with the menstrual cycle. On the last day of menstruation, the interface changes from Figure 2 to Figure 3. Clicking "Mark End" in Figure 3 ends the menstrual period recording and enters the follicular phase. The interface changes from Figure 3 to Figure 4 will then automatically switch. Then, according to the stages of the physiological cycle, the interface change state diagram 4 of Design 1 jumps to the interface change state diagram 5 of Design 1, and the interface change state diagram 5 of Design 1 jumps to the interface change state diagram 6 of Design 1. Design 2's main view is the homepage interface for a woman's menstrual cycle. When the APP enables intelligent prediction, and the menstrual cycle is in the follicular phase, the main view of Design 2 will automatically jump to the interface change state diagram 1 of Design 2. Based on the stages of the physiological cycle, the interface change state diagram 1 of Design 2 will automatically jump to the interface change state diagram 2 of Design 2, and the interface change state diagram 2 of Design 2 will automatically jump to the interface change state diagram 3 of Design 2. When the menstrual period begins during the luteal phase, clicking "Mark Start" in the interface change state diagram 3 of Design 2 will redirect the interface change state diagram 4 of Design 2, indicating the start of the menstrual period and the beginning of menstrual period recording. Design 2: Interface Changes (Figure 4) will change accordingly as the menstrual cycle progresses. When in the last day of the physiological period, the design 2 interface change state diagram 4 jumps to the design 2 interface change state diagram 5, and the "mark end" in the design 2 interface change state diagram 5 is clicked to end the record of the menstrual period and enter the follicular phase, and the design 2 interface change state diagram 5 automatically jumps to the design 1 interface change state diagram 6. The design 3 main view is the home page interface of the female physiological cycle. When the intelligent prediction is started on the APP, the design 3 main view automatically jumps to the design 3 interface change state diagram 1 when the physiological cycle is in the follicular phase. When entering the physiological period in the follicular phase stage, the "mark start" in the design 3 interface change state diagram 1 is clicked, and then the design 3 interface change state diagram 1 jumps to the design 3 interface change state diagram 2 to enter the menstrual period and start the record of the menstrual period. The design 3 interface change state diagram 2 will jump to the corresponding interface with the change of the physiological period time. When in the last day of the physiological period, the design 3 interface change state diagram 2 jumps to the design 3 interface change state diagram 3, and the "mark end" in the design 3 interface change state diagram 3 is clicked to end the record of the menstrual period and enter the follicular phase, and the design 3 interface change state diagram 3 automatically jumps to the design 3 interface change state diagram 4. Then, according to the stage of the physiological cycle, the design 3 interface change state diagram 4 jumps to the design 3 interface change state diagram 5, and the design 3 interface change state diagram 5 jumps to the design 3 interface change state diagram 6. The design 4 main view is the home page interface of the female physiological cycle. When the intelligent prediction is started on the APP, the design 4 main view automatically jumps to the design 4 interface change state diagram 1 when the physiological cycle is in the ovulation day. According to the stage of the physiological cycle, the design 4 interface change state diagram 1 automatically jumps to the design 4 interface change state diagram 2. When entering the physiological period in the luteal phase stage, the "mark start" in the design 4 interface change state diagram 2 is clicked, and then the design 4 interface change state diagram 2 jumps to the design 2 interface change state diagram 3 to enter the menstrual period and start the record of the menstrual period. The design 4 interface change state diagram 3 will jump to the corresponding interface with the change of the physiological period time. When in the last day of the physiological period, the design 4 interface change state diagram 3 jumps to the design 4 interface change state diagram 4, and the "mark end" in the design 4 interface change state diagram 4 is clicked to end the record of the menstrual period and enter the follicular phase, and the The design 5 main view is the home page interface of the female physiological cycle. The smart prediction is started on the APP, when the physiological period is in the ovulation day, the design 5 main view automatically jumps to the design 5 interface change state diagram 1. When the physiological period is in the ovulation day stage, the design 5 interface change state diagram 1 jumps to the design 5 interface change state diagram 2, enters the menstrual period, and starts the record of the menstrual period by clicking the "mark start" in the design 5 interface change state diagram 1. The design 5 interface change state diagram 2 will jump to the corresponding interface with the change of the physiological period time. When in the last day of the physiological period, the design 5 interface change state diagram 2 jumps to the design 5 interface change state diagram 3, the record of the menstrual period is ended by clicking the "mark end" in the design 5 interface change state diagram 3, enters the follicular phase, and the design 5 interface change state diagram 3 automatically jumps to the design 5 interface change state diagram 4. Then, according to the stage of the physiological period, the design 5 interface change state diagram 4 jumps to the design 5 interface change state diagram 5, and the design 5 interface change state diagram 5 jumps to the design 5 interface change state diagram 6.

A model for a cardiovascular amplitude metric characterizes timewise changes in a cardiac metric for a user based on a follicular mean of the cardiac metric and a luteal mean of the cardiac metric. The cardiovascular amplitude metric can be calculated for the user, e.g., based on data from a wearable physiological monitor, and used to provide coaching for fertility, hormonal health, fitness, and so forth.

The present invention is a method of a non-continuous administration of a pharmaceutical to a female for a condition associated with the female's menstrual cycle, compromising in the administration of either 7α-Acetylthio-3-oxo-17α-pregn-4-ene-21,17-carbolactone, (+)-(S)-2-(6-methoxynaphthalen-2-yl) propanoic acid or RS)-2-(4-(2-methylpropyl) phenyl) propanoic acid. The active ingredients to be manufactured into a tablet or chewable formulation rich in cocoa flavonols such as dark chocolate no more than 65%. A method of inhibiting one or more symptom of premenstrual syndrome / late luteal phase dysphoric disorder compromising of administering to a female in need of treatment an effective amount of a compound. The first dose to be given at the onset of the premenstrual symptoms. This can be given two to four times a day up to seven days as directed. This is intended to be a short course of therapy to alleviate the symptoms of premenstrual syndrome / late luteal phase dysphoric disorder.

The invention relates to a method for inducing ovulation of a female host. The method comprises the step of giving a non-polypeptide cyclic adenosine 3',5'-monophosphate (cAMP) (cAMP) level modulator to the female host. The invention provides a method for specifically giving a phosphodiesterase inhibitor before a luteal phase of the ovulatory cycle of the female host. Preferentially, the cAMP level modulator comprises the phosphodiesterase inhibitor, particularly four types of inhibitors of the phosphodiesterase inhibitor.

The invention discloses a traditional Chinese medicine composition capable of treating menstrual flow and infertility caused by thin endometrium and a preparation method thereof. 1~6 parts, 1~9 parts of cornus, 1~6 parts of fried white peony, 0.5~3 parts of fried angelica, 1~9 parts of Chuanxiong, 1.5~9 parts of Suanzaoren, 1~9 parts of Anemarrhena, cloud Made from 1-6 parts of Poria cocos, 1-6 parts of fried Codonopsis pilosula, and 1-12 parts of fried Atractylodes macrocephala. The present invention screens and obtains the prescription through a large number of clinical studies, and the research results show that the Chinese medicine compound can effectively improve the symptoms of less menstrual flow and infertility of the kidney yin deficiency type, increase menstrual flow, and promote endometrial hyperplasia and follicular growth in the late menstrual period. Develop and improve serum E2 and LH levels during ovulation, improve E2 and P levels in the mid-luteal phase, increase the thickness of the endometrium in the mid-luteal phase, increase the volume of the endometrium, and enrich the subendometrial blood perfusion in the mid-luteal phase, thereby increasing the endometrial volume Receptivity, promote embryo implantation, and no toxic side effects, safe and reliable medication.

The present invention relates to a composition which is for preventing and ameliorating or treating premenstrual syndrome symptoms, and includes: (a) a Chrysanthemum zawadskii extract; (b) a mixture of the Chrysanthemum zawadskii extract and a malt extract; or (c) a mixture of the Chrysanthemum zawadskii extract, the malt extract, and an aloe extract. Specifically, the present compositions effectively inhibit the secretion of prolactin from pituitary cells, which is a phenomenon that appears during premenstrual syndrome, thereby increasing the secretion of progesterone, which is reduced during the luteal phase of women, and can thus be advantageously used as a composition for preventing and ameliorating or treating women's premenstrual syndrome.

A bed can include a temperature control system. The temperature control system can include at least one processor and computer memory storing instructions that, when executed by the at least one processor, cause the at least one processor to determine that a female sleeper is in her luteal phase; and operate the temperature control system, based on the determination that the female sleeper is in her luteal phase, to alter a temperature of at least a portion of the bed system according to a temperature scheme.